Chirality
What is Chirality?
Benefits of Chirality
Examples of Chirality
Chiral Publications
Chiral Drugs
Asomex -  International Tie-ups / Presence
Company Profile News & Events Downloads Feedback Contact Us
Chirality - Today and Tommorrow's way of treatment
Home : Chirality >> Chiral Publications
Chirality – Today and Tomorrow’s Way of Treatment
Reprinted from- The future lies in chiral purity: A perspective. J Indian Med Assoc. 2007; 105(4):177-8.
Dr. Mukund Gurjar, Director – R&D, Emcure Pharmaceuticals Limited
The following are the publications based on Emcure’s chirally pure products and activities.

Results of two multicentric, comparative, randomized, parallel group clinical trials to evaluate the efficacy and safety of Dexketoprofen Trometamol in the treatment of dental Pain and dysmenorrhoea in Indian patients. Balani M, Gawade P, Maheshgauri S, Ghole S, Shinde V, Sathe V, Journal of Clinical and Diagnostic Research, JCDR doi: 266-252-289 (published online first 23rd Sep 2008)

Efficacy and safety of intravenous S-Pantoprazole in the treatment of moderate to severe gastroesophageal reflux disease (GERD) and / or peptic ulcers. Suresh Jain, Jayprakash Rathi, Pharmacologyonline 2: 733-741 (2008).

Efficacy and safety of a fixed-dose combination (FDC) of S-Amlodipine +S-Metoprolol versus FDC of Amlodipine + Metoprolol and FDC of Amlodipine + Atenolol in the treatment of patients with hypertension and angina pectoris (SMART-SESA study). JPS Sawhney, P.Agarwal, I Basu, Cardiology Today, Vol. XII, No.4, July-August 2008, pg. 182-186. Ten mg dexrabeprazole daily is as effective as 20 mg dexrabeprazole daily. Rajendra Kanakia, Suresh Jain, World Journal of Gastroenterology, July 2008; 14(28): 4586-4587

Review of a novel proton pump inhibitor – Dexrabeprazole. Suresh C.Jain, Gastroenterology Today, April-June 2008, Vol. XII, No.2, pg.79-83.

Efficacy and safety of S-Metoprolol extended release tablet in the management of congestive heart failure. (SMART-HF Study), Indian Medical Gazette, Vol. CXLII, No. 5, pg.194-97.

S-Metoprolol, The 2008 clinical review. Arup Dasbiswas, Suresh Shinde, Debasri Dasbiswas, Journal of Indian Medical Association 2008, 106.259-62

Results of a multi-centric, comparative clinical trial on efficacy and safety of Eszopiclone in Indian patients. Sanjay Phadke, Jyoti Shetty, Indian Journal of Sleep Medicine, 2008, 3.1, 20-24

Pharmacokinetics of S(-)Amlodipine and Atorvastatin on oral administration of fixed dose combination tablet in healthy subjects. Dharmendra Ved, Shirkant Rane, Indian Medical Gazette, January 2008, Vol. CXLII, No. fd1, pg. 24-30.

Comparative study to evaluate the effect of S-Amlodipine versus Amlodipine on office and ambulatory blood pressure in mild to moderate hypertensives. D.Basu, Indian Medical Gazette, December 2007, Vol./ CXLI, No.12, pg. 493-497

An open label, randomized, comparative, multicentric clinical trial of R-Sibutramine versus racemic Sibutramine in the management of obesity. Uday Phadke, Vaishali C.Deshmukh, Shrihari Dhorepatil, Shailaja Kale, R.T.Borse, V.P.Mandora, P.M.Gandhi, Indian Medical Gazette, November 2007, Vol. CXLI, No.11, pgs.430-440

A randomized, cross over study to determine bioequivalence of two brands of Dexibuprofen 400 mg tablets in healthy Asian adult male subjects of Indian origin. S. Menon, N. Kadam, G. Patil and P. Mhatre, International Journal of Clinical Pharmacology and Therapeutics, Vol. 46 – No. 1/2008 (48-54)

Pharmacokinetics of R- and S-enantiomers of Sibutramine in healthy volunteers. S.Menon, V.Gokarn, V.Patil, B.Khairnar. Indian Medical Gazette, October 2007, Volume CXLI, No.10, pg. 409-413

Pharmacokinetics of S(-)Amlodipine and Hydrochlorothiazide on oral administration of Asomex-D5 tablet. D.Ved, S.Rane, Indian Medical Gazette, September 2007, Volume CXLI, No.9, pg. 378-383

SESA IV, Results of a Multicentric post-marketing surveillance study on safety and efficacy of S-amlodipine in the treatment of hypertension. SESA IV study group, Cardiology Today Vol. XI No.5 September-October 2007.

Pharmacokinetics of S-Amlodipine and S-Metoprolol on oral administration of Asomet-XL Tablet. S.Menon et al, Indian Medical Gazette, August 2007, Vol. CXLI, No.8, pg. 331-336.

Recent advances in chirally pure proton pump inhibitors. Vikas Pai et al., Journal of Indian Medical Association, 2007, Vol. 105, pg. 469-474.

Anorexic effect of R-sibutramine: comparison with (RS)-sibutramine and S-sibutramine. Subhash. L. Bodhankar, Prasad A. Thakurdesai, Shrawan Singhal, Vaibhav Gaur, Indian Journal of Physiology and Pharmacology, 2007, 51(2), 175 – 178.

Pharmacokinetics of R(+) and S(-) enantiomers of rabeprazole in healthy volunteers. Menon S., Gokarn V., Patil V., Indian Medical Gazette, July 2007, 284-288.

Safety and efficacy of S(-)Amlodipine in the management of stage - I and stage - II hypertension: The SESA-IVA experience at Imphal. K. Singh, Indian Medical Gazette, June 2007, 230-234.

Randomized, double-blind, comparative study of dexrabeprazole 10 mg versus rabeprazole 20 mg in the treatment of gastroesophageal reflux disease. V. Pai, N. Pai, World Journal of Gastroenterology, 2007, Aug 14, 13(30), 4100-4102.

Comparative clinical study of the efficacy and safety of a S-metoprolol ER tablet versus a racemate metoprolol ER tablet in patients with chronic stable angina. P. Aneja, A. Srinivas and A. Das Biswas; International Journal of Clinical Pharmacology and Therapeutics, Volume 45, No. 5/2007 (May), 253-258.

Pharmacokinetic bioequivalence study of two formulations of Eszopiclone 3 mg tablets under non-fed condition in healthy adult Asian male subjects of Indian origin. Sasikumar Menon, Neeta Kadam; Sreedevi Pillai; Vijay Gokarn; Indian Medical Gazette, May 2007, Vol. CXLI, pg. 199 - 205.

Safety & Efficacy of S-Metoprolol in the Treatment of Patients with Diabetes Mellitus and Hypertension (SMART-DIMENSION Study); Talwalkar PG; Indian Medical Gazette, April 2007, Vol. CXLI, No.4, pg. 139-144.

Unichiral Drugs – More potent and less side-effects; Asok Kumar Kar; Journal of Indian Medical Association, April, 2007, Pg. 166.

Differential properties of enantiomers of commercially available racemates; V.Gulati; Journal of Indian Medical Association, April, 2007, Pgs.173-174.

The future lies in chiral purity : A perspective Mukund Gurjar; Journal of Indian Medical Association, April, 2007, Pgs. 177-178.

S-Amlodipine: The 2007 clinical review; Hemant P.Thacker; Journal of Indian Medical Association, April, 2007, Pgs. 180-190:

Review of Safety and Efficacy of S-Amlodipine in the Management of Angina; Gulati V; Indian Medical Gazette, February 2007, Vol. CXLI, No.2, pg. 70-73. Results of S-Amlodipine and Atorvastatin in Patients of Hypercholesterolemia and Hypertension Evaluation (SAPHE) Study-2; Pai V; Indian Medical Gazette, January 2007, Vol. CXLI, No.1, pg. 11-16.

Results of S-Amlodipine and Atorvastatin in Patients of Hypercholesterolemia and Hypertension Evaluation (SAPHE) Study-1; Sangle S; Indian Medical Gazette, December 2006, Vol.CXL, No.12, pg. 539 – 544.

An open-label, non-comparative, prospective study to evaluate efficacy of L-Carnitine in the management of fatigue; Nucarnit Study Group, India; Indian Medical Gazette, November 2006, Vol.CXL, No.11, pg. 500-504

Comparative clinical trial of S-Pantoprazole versus racemic pantoprazole in the treatment of gastro-esophageal reflux disease; Vikas G.Pai, Nitin V.Pai, Hemant P.Thacker, Jaisingh K Shinde, Vijay P.Mandora, Subhash S.Erram; World Journal of Gastroenterology, October 7, 2006; 12(37); pg.6017-6020.

Development of safer molecules through chirality; P.A.Patil, M.A.Kothekar; Indian Journal of Medical Sciences, October 2006,Vol.60, No.10, pg. 427-437

The effect of Rabeprazole and its isomers on aspirin and histamine-induced ulcers in rats; S.L.Bodhankar, B.B.Jain, B.P.Ahire, R.B.Daude, P.P.Shitole; Indian Journal of Pharmacology, October 2006, Vol. 38, Issue 5, pg.357-358

Multicentre Clinical Evaluation of a Fixed-Dose Combination of S-Amlodipine and Atenolol in the Treatment of Mild to Moderate Hypertension; SESA-III Study Group; Indian Medical Gazette, October 2006, Vol.CXL, No.10, pg.464-466.

Efficacy and safety of a fixed dose combination of S-Amlodipine and Losartan; Nusar-AM Study Group; Indian Medical Gazette, September 2006, Vol. CXL. No.9, pg. 406-408..

An open-label, non-comparative, prospective study in clinical setting to assess the efficacy and safety of R-Ondansetron tablet in nausea and vomiting; Zordil study group, India; Indian Medical Gazette, August 2006, Vol.CXL., No.8, pg.367-70.

Efficacy and Safety of a fixed dose combination of S-Metoprolol 25 mg and Hydrochlorothiazide 12.5 mg Tablet in the Treatment of Mild to Moderate Hypertension; Thockchom Sachin Deba Singh; Indian Medical Gazette, July 2006, Vol. CXL., No.7, pg.314-317.

Results of an open-label, Prospective, Non-comparative Study to Assess the Efficacy of S-Pantoprazole in Clinical Practice; S-Pantoprazole Study group, India; Indian Medical Gazette, June 2006, Vol. CXL, No.6, pg.285-289.

Efficacy and safety of Efavirenz in combination with other antiretroviral agents in the treatment of HIV infected Indian patients; Efcure PMS study group; Indian Medical Gazette, May 2006,Vol.CXL,No.5, pg.211-214.

Recent Developments: Chiral switch in PPI therapy: S (-) Pantoprazole; Pai V., Pai N; British Medical Journal, South Asia Edition, April 2006, Vol 22, No.2,pg.112

Results of SMART-II study on efficacy and safety of S-Metoprolol extended release tablet; SMART-II Study Group; Indian Medical Gazette, February 2006, Vol.CXL,No.2, pg.72-75.

Safety and Efficacy of S-Metoprolol Succinate Extended Release tablet in the Treatment of Hypertension Coexisting with COPD – An Open-label, Non-comparative, Prospective Clinical Study; V.P.Mandora; Indian Medical Gazette, January 2006,Vol.CXL,No.1, pg.28-32.

The SESA-II Study: Safety and Efficacy of S(-)Amlodipine in the treatment of Hypertension; SESA-II Study group, India; Indian Medical Gazette, December 2005, Vol. CXXXIX, No. 12, pg.529-533.

Efficacy and safety of S-Metoprolol extended release tablets in the management of Hypertension – Results of multicentric, prospective, clinical study; P.Aneja, A.Srinivas, G.Janardhan; Indian Medical Gazette, November 2005, Vol. CXXXIX, No.11, pg 485-487.

Recent advances in proton pump inhibitor therapy: S-Pantoprazole; Vikas Pai, Nitin Pai; Gastroenterology Today, October-December 2005, Vol.IX, No.4, pg.197-200.

Drug point: Chiral switches in the management of hypertension; Pathak L; British Medical Journal, South Asia Edition, October 2005, Vol.21, No.8, pg.688.

Efficacy and Safety of R-Ondansetron 4 mg versus Racemic Ondansetron 8 mg : Results of a Randomized, Double Blind, Multicentric Clinical Trial; J.Shinde, P.K.Joshi, V.P.Mandora, S.S.Erram; Indian Medical Gazette, October 2005, Vol. CXXXIX, No.10, pg.444-447.

The SESA-Angina Study – Safety and Efficacy of S(-)Amlodipine in Angina; Jagdish S.Hiremath; Indian Medical Gazette, September 2005, Vol.CXXXIX, No.9, pg.403-408.

MICRO-SESA-II – Safety and Efficacy of S(-)Amlodipine in the Treatment of Hypertension in Elderly Patients; SESA Study group, India; Indian Medical Gazette, August 2005, Vol. XXXIX, No.8, pg.353-358.

R-Ondansetron – A novel antiemetic; Jaisingh Shinde; Gastroenterology Today, July-September 2005, Vol. IX, No.3, pg.132-133.

The SMART Trial (S-Metoprolol Assessment in Hypertension Trial) The SMART Trial Study Group; Cardiology Today, July-August 2005, Vol.IX, No.4, pg 222 – 229.

HASTE – 201: Efficacy and safety of S (-) Atenolol in hypertensive patients who had experienced side-effects with racemic Atenolol; HASTE Study group, India; Indian Medical Gazette, July 2005, Vol.CXXXIX, No.7, pg.308-313.

MICRO-SESA-1 – Safety and Efficacy of S(-) Amlodipine in the treatment of isolated systolic hypertension; SESA Study group, India; Indian Medical Gazette, June 2005, Vol.CXXXIX, No.6, pg.243-250.

Multicentric Clinical Evaluation of S-Atenolol: Hypertension and Angina with S-Atenolol Evaluation Study (HASTE study); HASTE Study Group, India; JAMA-India, November 2004, Vol.3, No.11, pg. 85-88.

Multicentric, Clinical trial of S-Amlodipine 2.5 mg versus Amlodipine 5 mg in the treatment of Mild to Moderate Hypertension – A Randomized, Double-blind Clinical Trial; Lekha Pathak, M.S Hiremath, P.G Kerkar, V.G Manade; JAPI, March 2004, Vol. 52, pg.197-202.

Chirally Pure Drugs in Hypertension; Bhupesh Dewan; Postgraduate Medicine; 2004, Vol.18, pg.145-150.

Randomized, Double-blind, Parallel-group, Multicentric clinical trial of Atpure (S-Atenolol 25 mg) versus Racemic Atenolol 50 mg in stage 1 and 2 hypertension; L.Pathak , H.Thacker, S.Jayaram, S.Sharma,J.Mannikar, D.Apte; JAMA India, January 2004, Vo.3, No.1, pg.71-75.

Safety and Efficacy of S-Amlodipine – SESA study; JAMA-India, August 2003, Vol.2, No.8, pg.87-92.

Clinical Trial of S-Amlodipine 2.5 mg versus Amlodipine 5 mg in the Treatment of Hypertension; P.G.Kerkar; Indian Journal of Clinical Practice, April 2003, Vol. 13, No.11, pg.49-54.

A Randomized, Double-blind, Double dummy, Multicentric, Parallel Group, Comparative Clinical Trial of S-Amlodipine 2.5 mg Vs Amlodipine 5 mg in the Treatment of mild to moderate Hypertension; Hiremath M.S., Dighe G.D.; JAMA-India, August 2002,Vol.1, No.8;pg.86-92.

Home | Company Profile | Feedback | Contact Us | Sitemap.

This information contained in the website should not be construed as medical advice, a medical opinion or diagnosis. Emcure Pharmaceuticals Limited shall not be liable for any such interpretation and any action taken on the basis of such interpretation and consequences arising therefrom. As medical information and treatment guidelines are constantly evolving and changing, the prescriber is requested to update his/her information regularly before prescribing the medicines/products as mentioned in this website.

Emcure Pharmaceuticals Limited shall not be liable for any consequence due to lack of such updation. Emcure Pharmaceuticals Limited shall not be held liable for any damage or injury or liability or compensation or claim arising from any unauthorized or improper or un-advised or off-label or mis-diagnosed use of the medicines/products mentioned in this website or for any adverse effects arising out of any use, whether or not such reactions are documented in the published literature or prescribing information or are unexpected and not published hitherto including carcinogenicity, mutagenicity, any effect on fertility or pregnancy, any effect on pregnant women, nursing mothers, pediatric or geriatric patients. Emcure Pharmaceuticals Limited shall not be held liable for any adverse consequences of improper storage of the medicines/products by the doctor, patient, pharmacies or any other distribution partners.

All content related to Emcure Pharmaceuticals Limited’s corporate and business activities, as well as those of its associates included on Emcure Pharmaceuticals Limited’s site as well as on associated sites, such as text, graphics, logos, button icons, images, audio clips and software, is the exclusive property of Emcure Pharmaceuticals Limited and / or its associates, and is protected by applicable legislations concerning protection and preservation of intellectual property rights and international treaties relating thereto. The compilation (meaning the collection, arrangement and assembly) of all content on this site is also the exclusive property of Emcure Pharmaceuticals Limited and/ or its associates and is protected by applicable laws as stated above.